RE:RE:RE:RE:RE:RE:Delay in Phase 1 a --------Get over it I think there is 3 scenarios and you are missing the middle one.
1)1a failure - I agree looks remote at this stage but still possible. They are doing the final patients for a reason so their data counts towards any decision.
2) A sort of meh blob. Where we have little or no efficacy signal and we have to contend with the toxicities and the program still fails to ignite interest. Interest is delayed to 1b. My view, one or two somewhat prolonged SD with a background of toxicities falls into this category.
3) A clear (if small) efficacy signal that raises to the level of PoC and in a sense starts to validate the target (Sortilin) and the drug (th1902). There is potential for an inflection point there.
I'm certainly not waiting for statistical significance, that is a long way off.
SPCEO1 wrote: The scientists are going to have to wait for statistical significance but I do not think the market will wait that long. If things are moving in t he right direction and the early results indicate some activity with the drug, at least some investors are likely to start betting on TH as soon as that is apparent. To me, it is already about 90% apparent but the final official word on the phase 1a is stil required before anyone can feel 100% secure that TH has an intriguing future in cancer that will stand a very good chance of being proved out in phase 1b and phase 2.
Bucknelly21 wrote: So are you saying we are going to have to wait till 2a !?